Nasdaq

SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
Monthly Prescribing Reference

Skyrizi Now Available as a Single-Dose Injection for Plaque Psoriasis

Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...
Nasdaq

AbbVie Launches SKYRIZI As Single-dose 150 Mg Injection - Quick Facts

(RTTNews) - AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque ...
Healthline

Skyrizi Side Effects and Tips for Managing Them

Skyrizi may lead to mild side effects, including headaches, fatigue, injection site reactions, and upper respiratory infections. Serious side effects, such as an increased risk of infections, may ...
Healio

Skyrizi 150 mg injection available for plaque psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Skyrizi is now available as a single-dose 150 mg ...
Healthline

Skyrizi Interactions: Alcohol, Medications, and Others

Skyrizi is a prescription drug used to treat certain autoimmune conditions, such as Crohn’s disease, in adults. There are currently no known interactions between Skyrizi and other medications, alcohol ...